Related Experiment Video
Updated: Jan 13, 2026
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
The therapeutic potential of targeting LYAR in gastric cancer
Kai Qin1, Guo-Qiang Chen1, Jing-Wen Ling1,2
1Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, People's Republic of China.
Aim:
To investigate the expression of Ly1 antibody-reactive clone (LYAR) in gastric cancer (GC) tissues and predict potential drugs targeting its sensitivity.
Methods:
We assessed the standardized mean difference (SMD) of LYAR mRNA expression across 20 GC datasets (1,804 GC samples, 858 normal tissues) using multi-center high-throughput data, in-house immunohistochemistry, and CCLE cell expression data. Clinical and pathological relevance of LYAR was evaluated using metrics such as receiver operating characteristic curve, sensitivity, specificity, and likelihood ratios. Additionally, upstream transcriptional regulation and enrichment analyses were performed, and drug sensitivity analysis identified potential drugs for high LYAR expression.
Results:
LYAR expression was significantly upregulated in GC (SMD: 1.20, 95% CI: 0.89-1.51). The area under the curve was 0.89 (95% CI: 0.86-0.92), with sensitivity 0.74 (95% CI: 0.66-0.81) and specificity 0.89 (95% CI: 0.82-0.94). MYC potentially enhances LYAR expression, promoting GC progression. High LYAR expression indicates sensitivity to AZD compounds.
Conclusion:
LYAR overexpression promotes GC progression and tumorigenesis, suggesting its potential as a therapeutic target.
Insights
Ly1 antibody-reactive clone (LYAR) is upregulated in gastric cancer (GC), promoting tumor growth. High LYAR expression may predict sensitivity to specific AZD drugs, suggesting LYAR as a potential therapeutic target for GC.
Area of Science:
- Oncology
- Molecular Biology
- Biomarker Discovery
Background:
- Gastric cancer (GC) remains a significant global health challenge.
- Identifying novel biomarkers for GC diagnosis and treatment is crucial.
Purpose of the Study:
- To investigate the expression of Ly1 antibody-reactive clone (LYAR) in gastric cancer tissues.
- To evaluate LYAR as a potential diagnostic and therapeutic target in GC.
- To identify potential drugs targeting LYAR sensitivity in GC.
Main Methods:
- Analysis of LYAR mRNA expression across 20 GC datasets (1,804 GC samples, 858 normal tissues).
- Assessment of LYAR's clinical and pathological relevance using ROC curves, sensitivity, and specificity.
- Investigation of upstream transcriptional regulation and drug sensitivity analysis.
Main Results:
- LYAR expression was significantly upregulated in GC tissues (SMD: 1.20).
- LYAR demonstrated high diagnostic accuracy (AUC: 0.89, sensitivity: 0.74, specificity: 0.89).
- MYC may enhance LYAR expression, promoting GC progression; high LYAR expression correlated with sensitivity to AZD compounds.
Conclusions:
- LYAR overexpression promotes GC progression and tumorigenesis.
- LYAR serves as a potential diagnostic biomarker and therapeutic target for gastric cancer.
- Targeting LYAR may offer a novel therapeutic strategy for GC patients.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38Mitogens and the Cell Cycle